Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gastroesophageal reflux disease.

David Armstrong1

  • 1Division of Gastroenterology, HSC-2F55, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario Canada L8N 3Z5. armstro@mcmaster.ca

Current Opinion in Pharmacology
|October 11, 2005
PubMed
Summary

Gastroesophageal reflux disease (GERD) management is evolving. While proton pump inhibitors (PPIs) are effective, new drugs offer improved acid suppression and potential motility treatments are being explored.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seeking gastroenterological services during a pandemic: lessons from a large, national, population-based survey during the COVID-19 pandemic.

Journal of the Canadian Association of Gastroenterology·2026
Same author

Small intestinal microbial fiber metabolism dysfunction in celiac disease.

Nature communications·2026
Same author

Study protocol for a multiarm, randomized controlled trial to determine the effectiveness of community-based frailty rehabilitation to improve physical function in older adults: The OPTIMAL Fitness Trial.

PloS one·2026
Same author

Patient preferences in managing zinc deficiency in celiac disease: Insights to inform future clinical trial design.

Nutrition and health·2026
Same author

Research Code Sharing in Support of Gold Standard Science.

Journal of diabetes science and technology·2026
Same author

Interobserver agreement for the assessment of erosive reflux esophagitis: a post hoc analysis of clinical trial data.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2026

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Gastroesophageal reflux disease (GERD) is a prevalent global condition with variable symptoms and endoscopic findings.
  • Current GERD therapy primarily relies on acid-suppressing drugs, particularly proton pump inhibitors (PPIs).

Purpose of the Study:

  • To review the current landscape of GERD management.
  • To discuss advancements in acid suppression therapies and explore the role of motility agents.

Main Methods:

  • Literature review of recent developments in GERD pharmacotherapy.
  • Analysis of studies on novel proton pump inhibitors and potassium-competitive acid blockers.
  • Evaluation of research on gastrointestinal motility agents in GERD.

Main Results:

  • Proton pump inhibitors (PPIs) have transformed GERD treatment but have limitations.
  • Newer PPIs and reversible, potassium-competitive acid blockers offer enhanced acid suppression.
  • Motility agents show promise but face challenges in outperforming current PPIs.

Conclusions:

  • Despite advances, developing new GERD therapies that surpass PPIs in efficacy, applicability, and safety remains challenging.
  • Future GERD treatment may involve combination therapies targeting both acid suppression and motility.

Related Experiment Videos